Registry on Salvage Antiviral Treatment for Patients Experiencing ADV and / or CMV Reactivation Post Allogeneic HSCT (EPROS)

Cell Medica

Status: Terminated

Conditions: Infectious Complications Following HSCT

Treatments: Other: antiviral therapies for CMV and/or ADV

Study type: Observational

Funder types: Industry

Identifiers

NCT02873325

CM-2016-01

Details and patient eligibility

About

DESIGN:

Disease registry - non-interventional.

INDICATION: Patients failing first or subsequent line treatment for adenovirus and / or cytomegalovirus reactivation post allogeneic hematopoietic stem cell transplantation.

Full description

In this disease registry, data on approximately 120 allo HSCT patients who have received salvage treatment (second or later line) with any antiviral therapy for ADV and / or CMV post allogeneic HSCT will be documented; of these 120, at least 40 patients will have been treated with Cell Medica's immune reconstitution ACT as salvage therapy. The patients will be consented prospectively or retrospectively for collection of data. Data will be collected at baseline, 6 months and 1 year after commencement of salvage treatment. Retrospective data collection (for patients who underwent HSCT in 2010 or later) is permitted.

Enrollment: 1 patient

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

1. Written informed consent
2. Physician requested salvage (defined as refractory to first, requirement for second line or greater) treatment for ADV and / or CMV reactivation post allogeneic HSCT.